Back to News
Market Impact: 0.2
Regeneron Extends BARDA Agreement For Additional Ebola Treatment Supply
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to provide additional supplies of Inmazeb, its approved Ebola treatment, for U.S. preparedness efforts. The announcement disclosed no supply volumes or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
REGN0.55
More News
- Regeneron extends Ebola treatment supply deal with US government
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?